OZURDEX Drug Patent Profile

When do Ozurdex patents expire, and what generic alternatives are available?

Ozurdex is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in OZURDEX is dexamethasone. There are thirty-nine drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the dexamethasone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ozurdex

A generic version of OZURDEX was approved as dexamethasone by PANGEA on April 28^th, 1983.

Summary for OZURDEX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	95
Patent Applications:	6,175
Drug Prices:	Drug price information for OZURDEX
What excipients (inactive ingredients) are in OZURDEX?	OZURDEX excipients list
DailyMed Link:	OZURDEX at DailyMed

See drug prices for OZURDEX

Recent Clinical Trials for OZURDEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eclipse Life Sciences, Inc.	PHASE1
AbbVie	PHASE4
Tianjin Medical University Eye Hospital	PHASE4

See all OZURDEX clinical trials

Pharmacology for OZURDEX

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for OZURDEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009		RX	Yes	Yes

Expired US Patents for OZURDEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009

EU/EMA Drug Approvals for OZURDEX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Ozurdex	dexamethasone	EMEA/H/C/001140Ozurdex is indicated for the treatment of adult patients with macular oedema following either branch retinal-vein occlusion (BRVO) or central retinal-vein occlusion (CRVO).Ozurdex is indicated for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as noninfectious uveitis.Ozurdex is indicated for the treatment of adult patients with visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.	Authorised	no	no	no	2010-07-26
THERAVIA	Neofordex	dexamethasone	EMEA/H/C/004071Treatment of multiple myeloma.	Authorised	no	no	no	2016-03-16

International Patents for OZURDEX

See the table below for patents covering OZURDEX around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	051278	IMPLANTE BIOEROSIONABLE PARA TRATAR UNA AFECCION OCULAR Y METODO PARA PREPARARLO
Austria	E381319
Austria	E555779
Australia	2004204744	Biodegradable ocular implant
Australia	2005290240	Ocular implant made by a double extrusion process

Supplementary Protection Certificates for OZURDEX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1581193	C300552	Netherlands		PRODUCT NAME: VOOR GEBRUIK IN EEN WERKWIJZE VOOR DE BEHANDELING VAN MACULAIR OEDEEM; REG. NO/DATE: EU/1/10/638/001 20100727
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1581193	122012000081	Germany		PRODUCT NAME: DEXAMETHASON; REGISTRATION NO/DATE: EU/1/10/638/001 20100727
1429780	SPC/GB12/058	United Kingdom		PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1581193	SPC/GB12/047	United Kingdom		PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727

OZURDEX Market Dynamics and Financial Trajectory (FY Revenue, Coverage, Exclusivity, and Patent/Generic Risk)

Last updated: July 21, 2026

Executive summary: OZURDEX (dexamethasone intravitreal implant) is a niche ophthalmology product tied to a specialty, high-acuity indication set (DME, RVO, and related retinal edema). Commercial trajectory is shaped by (1) local market exclusivity and post-launch generic/biosimilar substitute risk, (2) payer and provider switching dynamics versus newer retina injectables and steroid alternatives, and (3) inventory and access constraints typical for specialty intravitreal devices. The remaining exclusivity and the strength and coverage breadth of the OZURDEX patent estate determine the timing and risk profile of “drop-in” competition, which then drives price erosion and share shifts. Without a cited financial baseline and jurisdictional commercialization data, a complete, accurate FY revenue and milestone forecast cannot be produced.

What is OZURDEX (dexamethasone intravitreal implant) and where is it sold?

Featured snippet answer: OZURDEX is a dexamethasone intravitreal implant for ophthalmic use, positioned in retinal edema workflows where clinicians seek steroid-mediated reduction in inflammation and vascular permeability.

What indications drive utilization and channel mix?

• Diabetic macular edema (DME)
• Macular edema following retinal vein occlusion (RVO)
• Other retinal edema presentations as reflected in labeling in specific markets

How does route and delivery constrain prescribing and adoption?

• Intravitreal implant procedures require trained retina specialists
• Administration schedules and re-treatment patterns affect treatment frequency, inventory turnover, and clinic throughput
• Switching depends on (a) physician outcomes, (b) payer authorization, (c) device handling logistics, and (d) perceived safety profile

Key market actors

• Branded originator commercial teams in each country
• Retina specialist practices and retinal clinics
• National and regional distributors
• Payers: national health systems, hospital formularies, and commercial insurers

How do payer coverage and hospital formularies affect OZURDEX sales growth?

Featured snippet answer: OZURDEX demand is most sensitive to formulary inclusion status, prior authorization burden, and the comparative economics versus competing steroid and anti-VEGF regimens.

Coverage levers that typically shift share

• Step therapy requirements (anti-VEGF first-line in some payer policies)
• Prior authorization rules based on treatment history
• Quantity limits and re-treatment intervals
• Tendering and group purchasing agreements in hospital systems
• Geographic rebate structures

Administration economics and clinic decision-making

• Total cost of care includes procedure time, clinic workflow, and downstream monitoring
• Device procurement contracts can reduce or amplify price pressure independent of FDA/EMA label dynamics
• Contracting terms can lead to “brand stickiness” even when clinical competition exists

Which competitors shape OZURDEX market dynamics in retinal edema?

Featured snippet answer: OZURDEX competes primarily against retina steroid alternatives and anti-VEGF-based strategies, depending on payer and clinical pathway.

Key competitive vectors

• Anti-VEGF agents for DME/RVO workflows (where payers and guidelines favor VEGF blockade)
• Other intravitreal corticosteroid formulations (sustained or depot steroids)
• Combination strategies where clinicians sequence or layer therapies

How does efficacy-safety trade-off drive switching?

• Steroid therapy substitution tends to hinge on glaucoma risk, cataract progression, intraocular pressure monitoring, and patient-specific risk tolerance
• Anti-VEGF switching tends to depend on treatment burden, response durability, and cost

What does that mean for pricing power?

• Strong clinical differentiation and payer-preferred positioning can delay price erosion
• When formularies favor newer agents or broader “first-line” coverage, OZURDEX pricing power weakens and volume can shift to alternatives

When does OZURDEX lose exclusivity, and what does that imply for generic entry risk?

Featured snippet answer: The timing of exclusivity loss determines the window for Paragraph IV-style challenges (where relevant) or non-infringing generic competition, which can rapidly compress realized prices.

What drives exclusivity expiration in intravitreal products

• Patent expiry for composition, device structure, release profile, and manufacturing methods
• Regulatory exclusivities (jurisdiction-specific)
• Market-specific data protection rules
• Patent-term adjustments and patent term extensions

Generic entry risk channels

• Full generic substitution: if formulation and release characteristics are not protected by composition/device patents
• “Authorized” or 3P supply competition: if licensing is in place or if manufacturing barriers are cleared
• Indication-specific carve-outs: even if one indication is protected, others can open

Litigation as a commercial variable

• Filed patent challenges can freeze or reshape launch timing
• Settlement terms can include:
  • Launch date commitments
  • Indemnities
  • Limited exclusivity periods or product launch restrictions in defined markets

What patents protect OZURDEX, and how strong is the patent estate?

Featured snippet answer: Patent estate strength depends on whether OZURDEX is protected across multiple layers: active ingredient use, implant composition/device geometry, controlled-release mechanism, and manufacturing method.

Patent coverage dimensions to map for infringement risk

• Composition of matter (if applicable to implant formulation)
• Device/implant structure and dimension constraints
• Controlled-release profile and polymer matrix systems
• Steroid dosing regimen and re-treatment algorithms (method-of-use)
• Manufacturing methods and process controls
• Process-related impurities and quality attributes
• Stability and storage conditions tied to shelf-life

How patent strength impacts financial trajectory

• A broad, staggered estate delays generic substitution and sustains margins
• Narrow coverage or early method-design-around opportunities accelerate price compression
• Settlement outcomes can convert legal risk into predictable revenue decline

What is the Orange Book status of OZURDEX, and does it list patents that predict launch timing?

Featured snippet answer: Orange Book listings can be used to map the patent expiries most likely to gate generic entry and to track any Orange Book-listed additional patents.

What to extract from Orange Book for financial modeling

• Patent numbers tied to the NDA/BLA
• Patent expiration dates and “listed” categories
• Remaining term by date bucket (next 12, 24, 36 months)
• Whether patents are composition, method-of-use, or formulation/device-related
• Any changes from supplemental filings over time

How does OZURDEX financial performance trend versus competing retina franchises?

Featured snippet answer: OZURDEX trends follow a specialty retina pattern where volume can remain stable but realized price declines when competitive formularies expand or when alternative steroids gain preferred status.

What to benchmark

• Volume growth versus value growth (price-only versus mix shifts)
• Treatment episodes and re-treatment frequency (proxy for demand resilience)
• Market access shifts (tender wins/losses in public systems)
• Share changes by region

What to expect when competition increases

• Margin compression driven by price concessions and rebate structures
• Faster volume switching if clinical pathways allow alternative steroid/anti-VEGF substitutions
• Higher sales and marketing spend to defend specialty center accounts

What does the pricing and reimbursement landscape imply for future OZURDEX revenue?

Featured snippet answer: Future revenue depends on whether OZURDEX remains formulary-stable and whether exclusivity/patent barriers delay generic or substitute competition.

Revenue drivers to model

• Net sales split: volume, price, and mix by indication and region
• Contracting: hospital tender outcomes and payer rebates
• Patient selection shifts driven by real-world risk constraints
• Clinic capacity and procedure scheduling constraints

Downside scenarios tied to competition

• Rapid price erosion if a substitute enters with broad access
• Reduced share if payers prefer alternative first-line strategies
• Inventory rebalancing if demand expectations shift near exclusivity cliffs

What is the most likely generic or “drop-in” competitive scenario for OZURDEX?

Featured snippet answer: The most likely competitive trigger is the end of the layered patent wall protecting the implant’s formulation/device functionality, coupled with successful manufacturing design-around and market access.

Commercial timeline mechanics

• Launch timing depends on:
  • Patent status changes
  • Litigation outcomes and settlement triggers
  • Distributor readiness and clinic onboarding
  • Payer reimbursement transitions after formulary updates

What to watch as early indicators

• Tender language and preferred product designations
• Price lists and contract renegotiations in high-volume retina centers
• New product entries in the same procedural category
• Biosimilar-type patterns do not usually apply to typical small-molecule drugs, but device- or formulation-substitute strategies can still pressure prices

How do litigation and regulatory events affect OZURDEX sales and valuation?

Featured snippet answer: Litigation and regulatory events typically affect sales through market access freezes, delayed launches, or renegotiated contracting, and affect valuation through cashflow predictability and risk discounting.

Key event categories

• Patent challenges (where they exist) and court rulings impacting launch timelines
• Settlements and consent decrees defining launch dates and permitted claims
• Regulatory updates that expand or restrict labeled use in key markets
• Supply chain disruptions impacting procedure scheduling and fulfillment

Key Takeaways

• OZURDEX commercialization is driven by retina specialist workflows, payer/formulary inclusion, and re-treatment dynamics typical of intravitreal products.
• The financial trajectory is most sensitive to (a) how long layered patents and exclusivity keep direct substitutes away and (b) whether newer steroid/anti-VEGF strategies gain payer-preferred status.
• Generic/substitute risk is gate-kept by the breadth of implant and manufacturing protections and by jurisdictional exclusivity timelines.
• Pricing power is sustained when OZURDEX remains formulary-stable; it erodes quickly when contract tenders and reimbursement policies shift toward substitutes.

FAQs

1. How do hospital tender contracts typically change OZURDEX net pricing in public systems?
2. What factors determine whether clinicians switch from OZURDEX to alternative steroid implants?
3. How do patent expiry dates translate into expected sales declines for intravitreal products?
4. What early indicators from the Orange Book (or local patent registers) signal higher generic risk?
5. How does re-treatment interval variability influence OZURDEX volume forecasts across DME versus RVO?

References

1. American Bar Association. “Orange Book and Patent Listings Overview.” (Accessed via general domain knowledge; no specific OZURDEX record cited.)